TD Cowen Maintains Buy on Exagen, Raises Price Target to $11
10/13/2026
Impact: 80
Healthcare
TD Cowen analyst Dan Bergstrom has maintained a 'Buy' rating on Exagen (NASDAQ: XGN) and increased the price target from $10 to $11.
AI summary, not financial advice
Share: